Key result
Serum indoxyl sulfate was independently associated with peripheral arterial stiffness in non-dialysis CKD stages 3-5.
Why the study?
Indoxyl sulfate is involved in vascular dysfunction and cardiovascular risk in CKD, but its role in peripheral arterial stiffness remains unclear.
Is serum indoxyl sulfate associated with peripheral arterial stiffness in patients with non-dialysis CKD stages 3 to 5?
Cross-Sectional
No
Is serum indoxyl sulfate associated with peripheral arterial stiffness in patients with non-dialysis CKD stages 3 to 5?
Serum indoxyl sulfate is independently associated with peripheral arterial stiffness in non-dialysis CKD patients, suggesting its potential as a vascular risk biomarker.
Answers are grounded in this paper and cite their sources.
IS association with PAS in non-dialysis CKD may support biomarker use; leaves open causal role and need for trials.
Indoxyl sulfate (IS), which is a protein-bound uremic toxin, is involved in vascular dysfunction and cardiovascular risk in subjects with chronic kidney disease (CKD). However, its role in peripheral arterial stiffness (PAS) remains unclear. This cross-sectional study evaluated the relationship between IS and PAS in patients diagnosed with CKD stages 3 through 5 who are not undergoing dialysis. Patients with CKD from a single center were enrolled. High-performance liquid chromatography analyzed the serum IS levels. PAS was evaluated using brachial–ankle pulse wave velocity (baPWV). IS was independently associated with PAS (odds ratio [OR]: 1.389 for 1 μg/mL increase in IS, 95% confidence interval [CI]: 1.086–1.775, p = 0.009) in a multivariable analysis after adjustment for age, hypertension, diabetes mellitus, blood pressure, lipid profiles, renal function, albumin, and proteinuria. Moreover, the mean baPWV (p = 0.010), left baPWV (p = 0.009), and right baPWV (p = 0.015) levels significantly correlated with the log-transformed IS (log-IS) levels. The area under the receiver operating characteristic curve for serum IS as a predictor of PAS was determined to be 0.667 (95% CI: 0.580−0.754; p = 0.0002). IS was associated with PAS in non-dialysis CKD stages 3–5, suggesting that IS may be a possible vascular risk marker. Future studies should address the nature of the relationship between IS and vascular dysfunction and assess therapeutic strategies to reduce IS.
No takes yet. Share an insight, caveat, or question.
Chern et al. (2025) conducted a cross-sectional in Non-dialysis chronic kidney disease stages 3 to 5. Serum indoxyl sulfate was evaluated on Peripheral arterial stiffness (PAS) (OR 1.389, 95% CI 1.086-1.775, p=0.009). Serum indoxyl sulfate was independently associated with peripheral arterial stiffness in non-dialysis CKD stages 3-5.
Synapse has enriched 10 related papers. Consider them for comparative context: